pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,272 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT825Endpoints630BioPharma Dive239onclive165Fierce Biotech91BioSpace90raps32globenewswire health
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • STAT+: In a major policy shift, Medicare proposes to ban vendors from providing remote monitoring services
    Medicare is proposing to ban vendors from providing remote patient monitoring services on behalf of doctors.
    STAT · 15d ago↗ source
  • Merck ADC, in China study, shows potential to replace chemo in lung cancer
    The results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for front-line lung cancer.
    BioPharma Dive · 15d ago↗ source
  • Braveheart, Attovia join next wave of biotech IPOs
    The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s already yielded several big-ticket IPOs.
← prev
page 10 of 51
next →
28
fda recalls22
fda press21
fda medwatch17
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
BioPharma Dive · 15d ago
↗ source
  • STAT+: Celcuity’s breast cancer drug approved, its first
    FDA's new CBER chief promises normalcy, an weight loss drug without GLP-1s, and more biotech news from The Readout
    STAT · 15d ago↗ source
  • Deaths from coronary artery disease have fallen, but more progress is within reach
    Managing risk factors is the key to further progress in reducing deaths from coronary artery disease, a new study finds.
    STAT · 15d ago↗ source
  • More health workers strike as Ebola cases in Congo exceed 2,000, including 754 deaths
    The number of confirmed cases of Ebola in Congo has reached 2,011, including 754 deaths, making it the the fastest-growing outbreak on record, authorities say.
    STAT · 15d ago↗ source
  • J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
    J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.
    BioPharma Dive · 15d ago↗ source
  • STAT+: Pharmalittle: We’re reading about a Biogen Alzheimer’s drug, skyrocketing 340B drug sales, and more
    An Alzheimer’s drug from Biogen slowed cognitive decline in a mid-stage trial at roughly comparable rates as approved medicines
    STAT · 15d ago↗ source
  • What to know about the parasitic diarrhea outbreak
    Fallout from the end of ACA subsidies, the FDA CBER acting director "on planet Earth," and more health news from Morning Rounds
    STAT · 15d ago↗ source
  • STAT+: Medicare Advantage insurers face new bipartisan scrutiny over AI and care denials
    Blumenthal, Hawley press UnitedHealth, Humana, CVS for documents related to using AI to deny or delay care.
    STAT · 15d ago↗ source
  • STAT+: Under a new leader, the FDA’s biologics center moves to steady itself after stormy chapter
    After his predecessor's turbulent tenure, Karim Mikhail is working to restore staff morale and revisit controversial rejections.
    STAT · 15d ago↗ source
  • STAT+: A new biotech startup tries to tackle obesity, but not in the way you might expect
    A new startup is making a bold move in the world of obesity drug development: It’s not working with the GLP-1 target that has taken the world by storm.
    STAT · 15d ago↗ source
  • Opinion: Why we still don’t know what foods are the source of the cyclospora outbreak
    “You cannot thin a system, defer the tools that would speed it up, and then wonder why the public is left guessing,” writes epidemiologist Katrine Wallace.
    STAT · 15d ago↗ source
  • STAT+: Swing Therapeutics acquired by medical VR platform XR Health
    Swing Therapeutics, developer of a digital treatment for fibromyalgia, has been acquired by medical virtual reality company XR Health.
    STAT · 15d ago↗ source
  • Flood of comments on White House grantmaking overhaul is largely negative, analysis shows
    An analysis of public comments on a White House proposal to change the way federal contracts and grants are doled out shows widespread opposition
    STAT · 15d ago↗ source
  • STAT+: FTC settles lawsuit with CVS Caremark over charges it manipulated insulin prices, impeded access
    The FTC settled a lawsuit against CVS Caremark over allegations that the company artificially inflated the price of insulin and impeded access to the diabetes treatment.
    STAT · 15d ago↗ source
  • CVS Caremark reaches settlement with FTC over insulin suit
    Terms of the deal announced Tuesday are very similar to those the FTC reached with Express Scripts earlier this year, including requiring the PBM to stop preferring higher cost versions of drugs on…
    BioPharma Dive · 15d ago↗ source
  • STAT+: Sales from controversial U.S. drug discount program rose to $100 billion last year
    Prescription drugs purchased under a controversial government discount program amounted to $100 billion in 2025, a 22.8% increase from the previous year.
    STAT · 16d ago↗ source
  • As cyclospora illnesses surge to a record, Michigan officials eye lettuce as a possible cause
    Infections from the diarrhea-causing parasite cyclospora are surging, and officials say early information points to lettuce or salad greens as a possible culprit.
    STAT · 16d ago↗ source
  • STAT+: Top Democrats question RFK Jr.’s health care advisory panel
    Democratic senators question presence of Trump donors, Tony Robbins on health care advisory panel.
    STAT · 16d ago↗ source
  • STAT+: Hospital chain HCA warns of lower profits as more patients go uninsured
    It's an early indicator of the fallout from the end of extra ACA subsidies.
    STAT · 16d ago↗ source
  • Judge orders Apple Tree partner to forfeit oversight of venture fund
    The ruling from a Cayman Islands court adds a new wrinkle to an ongoing legal dispute that’s already resulted in a bankruptcy filing — and a bid by general partner Seth Harrison for the firm’s port…
    BioPharma Dive · 16d ago↗ source
  • Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill
    Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.
    BioPharma Dive · 16d ago↗ source
  • STAT+: Anthropic’s Claude Science is coming for Kendall Square
    AI still has the potential to do more than reduce corporate head counts. Watch out, Kendall Square.
    STAT · 16d ago↗ source
  • Majority of new Ebola cases in eastern Congo are from unknown chains, as outbreak outpaces response
    The Ebola outbreak in eastern Congo “continues to outpace the response efforts,” the WHO’s emergencies chief said on Tuesday after returning from a trip to one of the worst hit…
    STAT · 16d ago↗ source